Eli Lilly tops profit estimates on boost from diabetes drugs

Eli Lilly and Co beat analysts’ estimates for quarterly profit and raised its full-year earnings forecast on Tuesday, as higher sales of diabetes drugs Trulicity and Basaglar offset competition for its erectile dysfunction treatment, Cialis.